1. Low-contrast visual acuity test is associated with central inflammation and predicts disability development in newly diagnosed multiple sclerosis patients.
- Author
-
Dolcetti, Ettore, Buttari, Fabio, Bruno, Antonio, Azzolini, Federica, Gilio, Luana, Di Caprio, Veronica, Lauritano, Gianluca, Borrelli, Angela, Galifi, Giovanni, Furlan, Roberto, Finardi, Annamaria, Musella, Alessandra, Guadalupi, Livia, Mandolesi, Georgia, Rovella, Valentina, Centonze, Diego, and Bassi, Mario Stampanoni
- Subjects
VISUAL acuity ,MULTIPLE sclerosis ,VISUAL evoked potentials ,VISION disorders ,DISABILITIES ,LOW vision - Abstract
Introduction: The visual system is a prominent site of damage in MS since the earliest phases of the disease. Altered low-contrast visual acuity (LCVA) test has been associated with visual impairment and retinal degeneration, predicting medium- and long-term disability. However, it is unclear whether LCVA may also represent a reliable measure of neuroinflammation and a predictor of disease evolution in the very early stages of MS. Methods: We explored in a group of 76 consecutive newly diagnosed relapsing-- remitting MS (RR-MS) patients without visual impairment or altered visual evoked potentials, the association between LCVA scores at 2.5% and 1.25% and clinical characteristics, including prospective disability evaluated after 1- and 2 years of follow-up. Associations between LCVA and the CSF levels of IL-10 at diagnosis were also analyzed. Results: A negative correlation was found between LCVA at 2.5% and Expanded Disability Status Scale (EDSS) evaluated at first (Spearman's Rho= -0.349, p =0.005, n =62) and second year (Spearman's Rho= -0.418, p <0.001, n =62) of follow-up, and negative correlations were found with Multiple Sclerosis Severity Score (MSSS) at first (Spearman's Rho= -0.359, p =0.004, n =62) and second year (Spearman's Rho= -0.472, p <0.001, n=62). All the data were confirmed by a mixed effect model, considering other clinical variables. A positive correlation was found between the CSF concentrations of IL-10 and LCVA at 2.5% (Spearman's Rho=0.272, p =0.020, n =76), and 1.25% (Spearman's Rho, = 0.276, p =0.018, n=76), also evidenced in a linear regression. Discussion: In MS patients at diagnosis, altered LCVA may be associated with CSF inflammation and represent a useful parameter to identify patients with worse disease course. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF